Home > Boards > US Listed > Miscellaneous > ZIOPHARM Oncology Inc (ZIOP)

Good move, keep watching. $2's are very

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Plegee Member Profile
 
Followed By 2
Posts 113
Boards Moderated 0
Alias Born 08/17/06
160x600 placeholder
WaterMill Asset Management Refutes Ziopharm Oncology’s Desperate, Low-Road Smear Campaign Business Wire - 11/28/2020 5:30:00 PM
Ziopharm Comments on Institutional Shareholder Services’ Recommendation to Reject WaterMill’s Attempt to Remove Half of Z... GlobeNewswire Inc. - 11/27/2020 5:31:54 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/27/2020 5:31:30 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/27/2020 5:27:52 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/27/2020 3:15:52 PM
 ISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Management’s WHITE Consent Card Business Wire - 11/25/2020 8:30:00 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/24/2020 4:46:01 PM
WaterMill Asset Management Sets the Record Straight Following Ziopharm’s Apparent Attempt to Mislead Shareholders & Rewrite... Business Wire - 11/24/2020 9:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/23/2020 5:24:16 PM
Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Share... GlobeNewswire Inc. - 11/20/2020 11:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/20/2020 6:01:35 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/19/2020 4:49:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 4:47:21 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/19/2020 4:14:47 PM
WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology Business Wire - 11/19/2020 9:30:00 AM
White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology PR Newswire (US) - 11/19/2020 9:00:00 AM
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2... GlobeNewswire Inc. - 11/19/2020 9:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/18/2020 5:17:22 PM
Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer GlobeNewswire Inc. - 11/17/2020 4:15:00 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/16/2020 2:49:22 PM
Ziopharm Oncology Appoints Mary Thistle to Board of Directors GlobeNewswire Inc. - 11/16/2020 8:30:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/13/2020 4:57:06 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/12/2020 3:08:10 PM
WaterMill Asset Management Releases Candid Q&As with Each of its Director Candidates for Election to Ziopharm Oncology’s Bo... Business Wire - 11/12/2020 9:00:00 AM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) Edgar (US Regulatory) - 11/5/2020 5:17:19 PM
Plegee   Friday, 02/07/20 07:42:34 AM
Re: eddyimano post# 1129
Post # of 1139 
Good move, keep watching. $2's are very possible. Another secondary to dilute shareholders. No progress in last five years. Clinical trial pulled with no management comment. Secondary issued with no management comments. Only one remaining "shot" on goal. Rosenberg NCI trial has still not dosed its first patient. IL-12 looks like a bust after being a primary strategy for years. Other Bio companies making great strides; our heralded Sleeping Beauty delivery system on the verge of being completely antiquated as CEO bumbles around letting timeline after timeline slip. Terrible CEO and probably not CMO caliber either (despite being a self proclaimed genius). Lawrence had MDA roots, I bet they do not miss him.

Still hope for share price improvement of course, but buying it as a lottery ticket should be your financial objective. PROF and AUPH are just two of dozens of better investments if you are looking for clinical stage or recently FDA approved companies. Was a bull on this company for years, now just a bag holder on my remaining few shares.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences